Repare Therapeutics - RPTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.33
  • Forecasted Upside: 399.52%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.47
▼ -0.18 (-4.93%)

This chart shows the closing price for RPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Repare Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RPTX

Analyst Price Target is $17.33
▲ +399.52% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Repare Therapeutics in the last 3 months. The average price target is $17.33, with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 399.52% upside from the last price of $3.47.

This chart shows the closing price for RPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Repare Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/17/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
2/14/2024HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $10.00Low
2/13/2024Bloom BurtonDowngradeBuy ➝ AccumulateLow
11/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00Low
10/16/2023Piper SandlerLower TargetOverweight ➝ Overweight$30.00 ➝ $25.00Low
9/25/2023Stifel NicolausBoost TargetBuy ➝ Buy$16.00 ➝ $17.00Low
8/17/2023HC WainwrightLower TargetBuy ➝ Buy$26.00 ➝ $25.00Low
6/9/2023Stifel NicolausUpgradeHold ➝ Buy$11.00 ➝ $16.00Low
6/9/2023HC WainwrightBoost Target$25.00 ➝ $26.00Low
5/11/2023Stifel NicolausLower Target$13.00 ➝ $11.00Low
3/17/2023HC WainwrightReiterated RatingBuy$25.00Low
2/27/2023Morgan StanleyLower TargetEqual Weight$15.00 ➝ $14.00Low
2/3/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$28.00 ➝ $15.00Low
1/6/2023Capital One FinancialReiterated RatingOverweight$28.00Low
11/17/2022HC WainwrightLower TargetBuy$38.00 ➝ $25.00Low
8/8/2022Morgan StanleyLower TargetOverweight$30.00 ➝ $28.00Low
6/6/2022HC WainwrightLower TargetBuy$54.00 ➝ $38.00Low
6/2/2022Piper SandlerBoost TargetOverweight$25.00 ➝ $30.00High
4/12/2022HC WainwrightReiterated RatingBuy$54.00High
4/12/2022Stifel NicolausDowngradeBuy ➝ HoldHigh
4/12/2022Piper SandlerLower Target$40.00 ➝ $25.00High
3/17/2022The Goldman Sachs GroupInitiated CoverageBuy$43.00High
11/18/2021Northland SecuritiesBoost TargetOutperform$40.00 ➝ $45.00Medium
11/10/2021Stifel NicolausLower TargetBuy$48.00 ➝ $47.00Medium
9/30/2021Bloom BurtonInitiated CoverageBuy$49.00Low
9/22/2021Stifel NicolausInitiated CoverageBuy$48.00Low
9/13/2021HC WainwrightInitiated CoverageBuy$54.00High
8/16/2021Morgan StanleyBoost TargetOverweight$45.00 ➝ $47.00High
6/28/2021GuggenheimInitiated CoverageBuy$46.00Medium
4/19/2021Morgan StanleyBoost TargetOverweight$41.00 ➝ $45.00High
3/1/2021Berenberg BankInitiated CoverageBuy$51.00Low
12/29/2020Northland SecuritiesReiterated RatingTop PickN/A
12/16/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $41.00High
10/28/2020Northland SecuritiesInitiated CoverageOutperform$38.00Medium
9/17/2020Bloom BurtonReiterated RatingBuyHigh
7/14/2020Morgan StanleyInitiated CoverageOverweight$37.00High
7/14/2020CowenInitiated CoverageOutperformHigh
7/14/2020The Goldman Sachs GroupInitiated CoverageNeutral$27.00High
7/14/2020Piper SandlerInitiated CoverageOverweight$40.00High
(Data available from 4/16/2019 forward)

News Sentiment Rating

1.61 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
10/19/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/17/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/16/2024
  • 3 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/17/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/16/2024

Current Sentiment

  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Repare Therapeutics logo
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.
Read More

Today's Range

Now: $3.47
Low: $3.35
High: $3.71

50 Day Range

MA: $5.68
Low: $3.47
High: $8.41

52 Week Range

Now: $3.47
Low: $3.08
High: $13.85

Volume

89,849 shs

Average Volume

99,492 shs

Market Capitalization

$128.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Repare Therapeutics?

The following equities research analysts have issued stock ratings on Repare Therapeutics in the last year: Bloom Burton, HC Wainwright, Piper Sandler, and Stifel Nicolaus.
View the latest analyst ratings for RPTX.

What is the current price target for Repare Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Repare Therapeutics in the last year. Their average twelve-month price target is $17.33, suggesting a possible upside of 399.5%. Piper Sandler has the highest price target set, predicting RPTX will reach $25.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Repare Therapeutics in the next year.
View the latest price targets for RPTX.

What is the current consensus analyst rating for Repare Therapeutics?

Repare Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RPTX will outperform the market and that investors should add to their positions of Repare Therapeutics.
View the latest ratings for RPTX.

What other companies compete with Repare Therapeutics?

How do I contact Repare Therapeutics' investor relations team?

Repare Therapeutics' physical mailing address is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. The company's listed phone number is 857-412-7018 and its investor relations email address is [email protected]. The official website for Repare Therapeutics is www.reparerx.com. Learn More about contacing Repare Therapeutics investor relations.